Funding

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Consult Part 2. Section III.1 Eligible Organizations for more information. Please refer to the website for detail announcement and key dates.

The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students and enhancing the research environment at applicant institutions. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million dollars per year of NIH support (in both direct and F&A/indirect costs) in 4 of the last 7 fiscal years. For institutions composed of multiple schools and colleges, the $6 million funding limit is based on the amount of NIH funding received by all the non-health professional schools and colleges within the institution as a whole. Consult Part 2. Section III.1 Eligible Organizations for more information.   Please refer to the website for detail announcement and key dates.

NOTE: 2025 application cycle is closed. Check the website again for 2026 updates. This track will aim to strengthen prevention, preparedness and response capacities in the face of future health crises, focusing on the priority emerging infectious diseases identified in the 2024 call: respiratory viruses, viral haemorrhagic fevers and arboviruses. The expected projects should adopt an interdisciplinary approach and contribute to advancing research in the service of public health. This call for proposals targets the three founding strands of the PEPR MIE: Section 1: Accelerating the acquisition of fundamental knowledge on emerging infectious diseases Section 2: Promoting innovation and developing new treatments, vaccines and other prevention, diagnostic and surveillance tools for emerging infectious diseases Section 3: Enabling public policies and society to cope with epidemic crises

The Lung Association is interested in applications that address the following types of clinical, basic, translational, and population health questions. Please refer to the websites for various funding opportunities and key dates for application.

APPLICATION DEADLINE: 1 December, 2025 11:59 p.m. ET The American Lung Association Catalyst Award is a mentored award meant to support outstanding investigators on the path to independence for research into the mechanisms of lung disease and general lung biology. Preference is given to projects that are novel, innovative in design/approach, utilize modern technologies, and incorporate a multidisciplinary collaborative training plan. The Catalyst Grant is for $50,000 per year, for up to two years. Grants are subject to annual review; the second year of support is based upon demonstration of satisfactory progress. When applicable, researchers are encouraged to investigate hypothesis‐driven research that will inform evidence‐based clinical practice or policy in communities across the United States. Proposals can include examining the cause and prevention of lung diseases like tuberculosis, asthma, COPD, and lung cancer, as well as management of lung disease.

Deadline to submit LOI is September 18, 2025.Refer to the website for other key dates. The Emerging Respiratory Pathogen Award was created to gain a better understanding of the pathobiology and the long term and immediate implications of respiratory infections. This includes emerging problems in known organisms and new and emerging pathogens. The Lung Association is interested in applications that address the following types of clinical, basic, translational, and population health questions: • A new understanding of the basic biology of respiratory viruses that could lead to better treatment and prevention • Understanding host factors that alter response to these infections • Understanding individual, regional, or social factors increasing or decreasing community spread of respiratory viruses • Case tracking and epidemiological approaches to understanding emerging respiratory viruses • The pathophysiology of the long term sequalae of respiratory viral infections, including COVID-19 • Key takeaways and lessons learned from the COVID-19 pandemic

European Respiratory Society (ERS) Long-Term Research Fellowships support researchers and clinicians in the early stages of their careers to carry out basic, translational or clinical research projects lasting between 6–24 months. Fellowship recipients conduct projects at research institutions outside of their home country, enabling fellows to access and learn research techniques that are not available at their home institutions. Long-term fellowships are awarded annually based on scientific merit as well as the skills and experience that fellows can bring to the host institution.

A career development fellowship sponsored by the National Institutes of Health (NIH) Fogarty International Center (FIC), this program supports awarded fellows from all 10 UC campuses as well as 22 affiliated international sites across 18 countries. UCGHI manages and supports the GloCal Health Fellowship.

The call for conference projects and publications covers all the thematic fields of the agency: - All research on HIV/AIDS, sexually transmitted infections (STIs), viral hepatitis, tuberculosis, including research on their co-infections; - Research on emerging and re-emerging infectious diseases, including arboviruses, respiratory viruses and viral hemorrhagic fevers. It is now possible to submit an application for funding continuously throughout the year, according to the following forecast schedule: January 15 – April 30 May 1 – August 31 September 1 – December 15

The ANRS Emerging Infectious Diseases, an autonomous agency of Inserm, supports research to provide scientific responses to infectious diseases in times of crisis and over the long term. It animates, coordinates, evaluates and finances research on HIV/AIDS, viral hepatitis, sexually transmitted infections, tuberculosis and emerging and re-emerging infectious diseases such as Covid-19, viral hemorrhagic fevers or arboviruses. It covers all areas of research: basic, translational and clinical research, research in public health and human and social sciences. The agency is developing a global health approach according to the One Health approach, which focuses on the links between human health, animal health and the environment. It thus strengthens France's response in the event of a crisis. The agency is part of an international effort to fight epidemics, in particular in close coordination with Europe and with a network of partners in low- and middle-income countries.

The Young Investigators Network focuses on funding and support in basic research on HIV/AIDS, viral hepatitis, STI, TB and emerging infectious diseases. This page posts various upcomomg opportunities.

The Association of Public Health Labs and the US Centers for Disease Control and Prevention partner to offer paid laboratory internships to train and prepare college students for careers at public health laboratories. Interns join public health laboratory teams to make an impact on protecting the health of our communities. Interns assist laboratory professionals working on meaningful projects, including infectious diseases.

NOTE: This is a yearly prize. The 2025 submission period is over. The 2026 period will open in February 2026. The ASU-Science Prize for Transformational Impact recognizes the importance of innovative, use-inspired research, intentionally designed to address pressing problems. This prize recognizes transformational research that uses innovative methods and approaches to identify problems and develop solutions with impacts on policy and decision-making. The research should be designed, executed, and communicated with explicit consideration for the problem(s) and how the research contributes to a solution outcome. Such work considers the values and interests of different communities, typically with attention to ethical, economic, political, or legal contexts. The research is often collaborative, drawing on multiple disciplines, driven by desired outcomes, and considering implications for policy and decision-making. Examples could include research that addresses human and environmental health, improves education and social outcomes, or evaluates beneficial use of synthetic biology and artificial intelligence technologies. Grand Prize Winner Receives: Each year, the grand prize winner will receive a prize of US$30,000. The grand prize-winning essay will be published in Science in print and online nd receive a 5-year digital subscription to Science.

Deadline for Submissions: November 1, 2025 The Prize aims to recognize researchers who have developed innovative advances with translational potential to impact women’s health globally. Contributions within any area of women’s health* will be considered. These may cover work in areas of female-specific conditions including maternal health and chronic gynecological diseases, reproductive health including contraception and infertility affecting all persons, or elucidation of sex- and gender-specific approaches to conditions that affect women differently or disproportionately. We encourage researchers who may have made significant advances in addressing questions in these fields at the intersection of translational research and clinical applications, or who are developing new drugs, diagnostic approaches, medical devices, or healthcare technologies, to apply. Researchers who have advanced development of new solutions that can be readily deployed in low- and middle-income countries are encouraged to apply. The Prize is awarded for outstanding research performed by the applicant and as described in a 1,000-word essay.

BWF’s financial support is channeled primarily through competitive peer-reviewed award programs. BWF makes grants primarily to degree-granting institutions on behalf of individual researchers. To complement these competitive award programs, BWF also makes grants to nonprofit organizations conducting activities intended to improve the general environment for science. Please refer to the website for upcoming funding deadlines.

The Career Award for Medical Scientists provides $700,000 awarded over five years for physician-scientists to bridge advanced postdoctoral/fellowship training and the early years of faculty service.

Application Deadline: 7 October 2025 The Career Awards for Medical Scientists (CAMS) is a highly competitive program that provides $700,000 awards over five years for physician-scientists, who are committed to an academic career, to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Please refer to the website for eligibility and details.

DEADLINE: 24 October, 2025 The Office of Disease Prevention Early Stage Investigator Lecture (ODP ESIL) award recognizes early career scientists who have made significant research contributions in prevention but who have not yet been awarded an R01 or R01-equivalent NIH research grant. In addition to meeting NIH's definition of an early stage investigator as of the nomination deadline, nominees should have: Innovative and significant research accomplishments in applied prevention research in humans, in areas that are relevant to ODP's mission Evidence of highly collaborative research projects, especially those that bridge disciplines to offer new approaches and ways of thinking in prevention research ODP is particularly interested in nominees conducting applied preventive intervention research to address common risk and protective factors for illness, injury, and the leading causes of death in the United States.

This Notice of Funding Opportunity (NOFO) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of heart, lung, blood, and sleep (HLBS) diseases and disorders. This NOFO is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization. Please refer to the website for detail announcement and key dates.

E.W. "Al" Thrasher Awards focus on projects that are changing pediatric clinical care. Each award is a novel approach to problems plaguing pediatrics. The award is open to applications focusing on any disease or topic within the umbrella of pediatrics, both in and outside the United States. Ideal applications for the Thrasher Award address significant health problems, offering the potential for practical solutions to these problems. Typically, the primary outcome is a health outcome in children. Solutions should be innovative and have the potential for broad applicability with low barriers to implementation. Projects with a shorter distance to clinical applicability are given priority.​

Contact: Roger Ptak Roger.Ptak@nih.gov Objective: This new initiative aims to support investigator-led, multidisciplinary research to define how HIV-driven alterations to immunometabolism affect immune cell regulation, cell-cell interactions, response to treatment, and, ultimately, tuberculosis (TB) and hepatitis B virus (HBV) progression. Elucidating and subsequently probing such mechanisms will lead to identification of candidate biomarkers of disease progression and potential targets for immune-modulatory treatment (i.e., host-directed therapy) to decrease TB and HBV risk in people living with HIV. Description: This initiative will advance laboratory-based research to elucidate immunometabolic pathways and mechanisms that can be exploited for new therapeutic and diagnostic strategies.

The goal of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to a low- or middle-income country (LMIC) early career research scientist who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries, with exceptions below (see Section III. Eligibility Information)). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Notice of Funding Opportunity (NOFO) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. Please refer to the website for detail announcement and key dates.

APPLICATION DEADLINE: 14 October 2025 17:00:00 Brussels time Objectives The Starting Grant supports excellent Principal Investigators starting or having recently started their own independent research team or programme. A Starting Grant Principal Investigator should have already shown evidence of the potential for research independence, for example, by having produced at least one important publication as its main author or a publication without the participation of their PhD supervisor. Size of ERC Starting Grants Starting Grants may be awarded up to a maximum of EUR 1 500 000 for a period of 5 years. The maximum size of the grants is reduced pro rata temporis for proposals of shorter duration. Profile of the ERC Starting Grant Principal Investigator The Principal Investigators shall have successfully defended their first PhD at least 2 and up to 7 years prior to 1 January 2026. Cut-off dates: Successful defence of PhD between 1 January 2019 and 31 December 2023 (inclusive). The eligibility period can be extended beyond 7 years in certain properly documented circumstances. See section 1.4 Admissibility, Eligibility, Resubmission Restrictions of the ERC Work Programme 2026.

APPLICATION DEADLINE: 05 November 2025 17:00:00 Brussels time Objective: The aim is to provide support for a small group of two to four Principal Investigators to jointly address ambitious research problems that could not be addressed by the individual Principal Investigators and their teams working alone. Synergy projects should enable substantial advances at the frontiers of knowledge, stemming, for example, from the cross-fertilization of scientific fields, from new productive lines of enquiry, or new methods and techniques, including unconventional approaches and investigations at the interface between established disciplines. The transformative research funded by Synergy Grants should have the potential of becoming a benchmark on a global scale. Principal Investigators must demonstrate the ground-breaking nature, ambition and feasibility of their scientific proposal. Principal Investigators must also demonstrate that their group can successfully bring together the scientific elements necessary to address the scope and complexity of the proposed research question. One of the Principal Investigators must be designated as the Corresponding Principal Investigator. At any one time, one Principal Investigator per Synergy Grant Group except the Corresponding one can be hosted or engaged by an institution outside of the EU or Associated Countries. Size of ERC Synergy Grants Synergy Grants may be awarded up to a maximum of EUR 10 000 000 for a period of 6 years. The maximum award is reduced pro rata temporis for projects of a shorter duration. This does not apply to ongoing projects. Profile of the ERC Synergy Grant Principal Investigators The 'Synergy Grant Group' applying for the ERC Synergy Grant must be made up of a minimum of two and a maximum of four Principal Investigators with competitive track records and, as necessary, their teams. Each of the Principal Investigators must present in the proposal a Curriculum Vitae and a Track Record as appropriate to their career stage. For further information, please see the ERC Work Programme 2026.

The European Research Council (ERC) is a funding organisation for frontier research. It aims to stimulate scientific excellence in Europe by funding the very best, creative researchers of any nationality and age, and supporting their innovative ideas. Researchers from anywhere in the world can apply for ERC grants provided the research they undertake will be carried out in an EU Member State or Associated Country.

European Respiratory Society (ERS) fellowships offer funding and support for research projects that address unmet needs in respiratory science and medicine. The fellowship programmes seek to actively involve ERS members in the earlier phases of their careers, enabling the training and career development of the next generation of respiratory researchers and clinicians.

APPLICATION DEADLINE: 12 December 2025 This award from the ESPID enables members to attend scientific meetings, training events and courses, except for the annual ESPID meeting for which separate schemes are available. Awards are worth up to 1. EUR 1,000 for international travel outside of Europe ‚ 2. EUR 600 for travel within Europe and ‚ 3. EUR 200 for travel within the applicant’s own country. The awards also cover accommodation and registration fees.

APPLICATION DEADLINE: 31 October 2025 This recognises young investigators in the field of paediatric infectious diseases. Both clinical and basic research is eligible. The winner will receive: 1. Euro 5,000 to be paid to the host institution for research purposes only. The host institution is not allowed to take any overhead on this amount (see declaration below) 2. At the time of being offered the award successful candidates will be invited to attend that year's ESPID Annual Meeting with registration, travel and accommodation being offered (if already registered, this will be refunded). Please be aware the travel and accommodation are subject to ESPID Rules and maximum amounts apply 3. The Young Investigator's medal 4. The winner will be asked to give a 5 minute presentation of their work at the ESPID Annual Meeting

L’Initiative encourages the implementation of projects that involve national pandemic response programs, the research community, civil society, and the private sector. The main project initiator must be a legal entity with a board of directors/executive committee and head office registered in an eligible country or in France.

From 1995 to 2025, over 4 million dollars in grants have been awarded for community projects and clinical or basic science research projects related to tuberculosis (TB) and chronic pulmonary diseases in pediatric and adult populations. Project Visibility: - Presented at national and international conferences - Published in peer-reviewed journals - Highlighted in local news conferences - Impact - Projects have enhanced clinical teachings and patient care of TB through numerous routes:

Fogarty Funding Opportunities - Searchable Database

The Global Infectious Disease (GID) research training program addresses research training needs related to infectious diseases that are predominantly endemic in or impact upon people living in developing countries. The training programs include a variety of research training options to match the needs of the developing country institution. Program focus on a major endemic or life-threatening emerging infectious disease, neglected tropical disease, infections that frequently occur as a co-infection in HIV infected individuals, or infections associated with noncommunicable disease conditions of public health importance in LMICs.

APPLICATION DEADLINE: 9 March, 2026 The International Research Scientist Development Award (IRSDA) provides support and protected time (three to five years) to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty (applicants must be at least two years beyond conferral of doctoral degree) for an intensive, mentored research career development experience. The experience will be in a low- or middle-income country (LMIC) as defined by the World Bank . Low-income, lower-middle-income and upper-middle-income countries are included. Applications are invited from early career investigators from any health-related discipline who propose career development activities and a research project that is related to the health priorities of the LMIC.

Non-NIH Funding Opportunities - Grants and Fellowships - Searchable Database

This Fogarty International website offers news, resources, and funding opportunities for global health researchers focused on TB. It features recent scientific publications, information on grants, updates on drug-resistant TB and TB-HIV coinfection, and progress toward the development of new vaccines.

The Fulbright-Fogarty Fellowships in Public Health are offered through a partnership between the Fulbright Program and the Fogarty International Center of the U.S. National Institutes of Health. These awards were established to promote the expansion of research in public health and clinical research in resource-limited settings. The Fulbright-Fogarty Fellowships were inaugurated in July 2011 with four fellows in Sub-Saharan Africa (Botswana, Malawi, and South Africa). Approximately 10 awards are made annually. Refer to the website for detail information.

The Fulbright-Fogarty Fellowships in Public Health are offered through a partnership between the Fulbright Program and the Fogarty International Center of the U.S. National Institutes of Health. These awards were established to promote the expansion of research in public health and clinical research in resource-limited settings. Fulbright-Fogarty Fellowships carry the same benefits as the traditional Fulbright Study/Research grants to the host country. The Fogarty International Center, NIH, will provide support to the research training site and may provide orientation for the fellows at the NIH.

The Fulbright-Fogarty Fellowships in Public Health are offered through a partnership between the Fulbright Program and the Fogarty International Center of the U.S. National Institutes of Health. These awards were established to promote the expansion of research in public health and clinical research in resource-limited settings. Fulbright-Fogarty Fellowships carry the same benefits as the traditional Fulbright Study/Research grants to the host country. The Fogarty International Center, NIH, will provide support to the research training site and may provide orientation for the fellows at the NIH.

The Global Health Innovative Technology Fund (GHIT Fund) established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs. Following the COVID-19 pandemic, the GHIT Fund has expanded its disease scope by adding selected Emerging and Re-Emerging Infectious Diseases for the Screening Platform. DEADLINE: 7/4/2026

Usually application due in November; application opens in August. The Global Health Fellowship Program is a 12-month clinical research training program for post-doctorate trainees and doctoral students in the health professions, sponsored by the NIH’s Fogarty International Center (FIC) in partnership with several NIH Institutes and Centers.

ASTMH offers a variety of fellowships and awards for members and, in some instances, non-members, and Early- and Mid-Career Professionals. To support the professional growth of early- and mid-career professionals, the Society offers the Benjamin H. Kean Travel Fellowship in Tropical Medicine, Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases, Centennial Travel Award in Basic Science Tropical Disease Research and the Robert E. Shope International Fellowship in Infectious Diseases. See the URL for criteria and deadlines.

THIS CALL IS LED EVERY 2 YEARS. NEXT CALL WILL BE IN APRIL 2027. The biennial EDCTP Prizes recognise outstanding individuals and research teams from Africa and Europe who have made significant achievements in their research field. Additionally, the awardees will have made major contributions to strengthening clinical research capacity in Africa and supporting South-South and North-South networking. The following prizes are available: Dr Pascoal Mocumbi Prize (€50,000) The Dr Pascoal Mocumbi Prize aims to reward an individual in recognition of his/her outstanding achievements in advancing health research and capacity development in Africa with significant impact on the wellbeing of the African population. Outstanding Research Team Prize (€50,000) This prize is awarded to outstanding research teams in sub-Saharan Africa and Europe working on HIV/AIDS, tuberculosis, malaria and neglected infectious diseases. Outstanding Female Scientist prize (€20,000) The prize is awarded to female scientists who have made a significant scientific contribution and built measurable impactful research capacity through training and mentorship for the future generation of researchers/scientists in Africa. Four Scientific Leadership Prizes (€15,000 each) Two Scientific Leadership Prizes (one woman and one man) for researchers who are permanent residents of an EU Member State or a country associated with the Horizon Europe programme.

The National Institutes of Health (NIH) participating Institutes, Centers, and Offices (ICOs), in collaboration with the Global Alliance for Chronic Diseases (GACD), invite applications for implementation research that aims to improve the availability of effective, efficient, integrated, patient-centered, safe, and timely care for people living with multiple long-term conditions (non-communicable disease (NCD) multimorbidity) in low- and middle-income countries (LMICs) and/or within American Indian/Alaska Native (AI/AN) populations in the United States. This Notice of Funding Opportunity (NOFO) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support awards). Applications will be accepted from US and World Bank-defined LMIC institutions only. Please refer to the website for detail announcement and key dates.

Global Health Travel Awards (for the Global Health Series) are to enable attendance of scientists, physicians, fellows or students from countries where the meeting topic health problems are endemic. The purpose of providing travel awards is to add to the diversity of experiences represented by participants at each meeting. The award will cover conference-related expenses to include: meeting registration, lodging, airfare and ground transportation from host airport to the resort. The amount of the awards will vary, depending on where awardees are coming from and the extent of their need.

This is a limited competition. The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). The purpose of this Notice of Funding Opportunity (NOFO) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding broadly-experienced pool of promising later stage postdoctoral fellows and junior faculty scholars who have made a commitment to independent clinical and translational science research careers (i.e., tenure-track or equivalent faculty positions) to facilitate their timely career advancement and continued engagement in research (i.e., sectors including academia, industry, nonprofit and government). Please refer to the website for detail announcement and key dates.

This is a limited competition. The National Center for Advancing Translational Sciences (NCATS) will award Ruth L. Kirschstein National Research Service Award (NRSA) Postdoctoral Institutional Research Training Grants for the Clinical and Translational Science Awards (CTSA) Program (T32) to eligible institutions to create, provide, and disseminate clinical and translational science training and career support programs that enhance postdoctoral research training of individuals with doctoral degrees (these include, but are not limited to, the following: D.M.D., DC, DO, DVM, OD, DPM, ScD, EngD, DrPH, DNSc, DPT, PharmD, ND [Doctor of Naturopathy], DSW, PsyD, as well as a doctoral degree in nursing research) and help ensure a pool of clinical and translational scientists trainees are equipped with the knowledge, skills and abilities to advance diagnostics, therapeutics, clinical interventions, and behavioral modifications that improve health and support meaningful translational science research projects that address demonstrable needs among stakeholder communities. Please refer to the website for detail announcement and key dates.

This Notice of Funding Opportunity (NOFO) invites eligible academic or research institutions to apply for funding support to purchase latest scientific equipment that will enhance and modernize research-supporting operations of existing shared biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this NOFO is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. The NOFO does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities.

Applications for the third round of the New York State Biodefense Commercialization Fund are now closed. Please check back for updates on the program. The $40 million Biodefense Commercialization Fund was created to encourage and accelerate the development and commercialization of solutions for serious infectious disease threats, including COVID-19 and its variants, while fostering the creation of new life science businesses and supporting industry growth. The Fund has offered grants to startup companies and academic institutions that are developing promising diagnostics, vaccines, therapeutics, and such other innovations as epidemiological surveillance tools, environmental controls, and clinical care advances that address or mitigate infectious disease threats. For the current application period, New York State seeks applications focusing on the specific areas of interest: - Novel platforms for development of rapid Point-of-Care (POC) diagnostics (examples include, but are not limited to, CRISPR and/or Isothermal-based platforms) with priority given to POC diagnostics that can perform as well as or better than existing lab tests. - Processes that integrate easy-to-use sample preparation and allow for access in low resourced settings. - Novel tools for sequencing and serology-based tests that support infectious disease and pathogen surveillance

The Small Business Innovation Research (SBIR) Program is an important funding mechanism that the National Institutes of Health (NIH) uses to develop innovative solutions that address public health challenges. A major objective of the program is to facilitate the commercialization of technologies developed by small business concerns (SBCs). Yet, the development of biomedical products is often impeded by a significant funding gap between the end of the SBIR Phase II award and the commercialization stage. This Notice of Funding Opportunity (NOFO) invites SBIR grant applications from SBCs to support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and which will require eventual Federal regulatory approval/clearance. The purpose of this NOFO and the resulting Phase IIB awards is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. Projects proposed under this NOFO MUST be relevant to the NHLBI mission (see B. Scientific/Technical Scope). This NOFO is specifically intended to benefit clinical practice by accelerating the commercialization of novel products that require ultimate approval/clearance by a Federal regulatory agency. This NOFO will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product as indicated by the applicant’s ability to secure independent third-party investor funds that equal or exceed the requested NHLBI funds, and competitive preference and funding priority to applications that show a strong potential for clinically relevant commercial products, as evidenced by the applicant’s ability to secure independent third-party investor funds equal to or exceeding the total requested costs. Please refer to the website for detail announcement and key dates.

NIH NIAID - Grants and Fundings - Searchable Database

The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote the dissemination and implementation of evidence-based interventions among relevant communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters remain relevant. All applications must be within the scope of the mission of one of the Institutes/Centers listed in the notice. Application DEADLINE: Multiple dates, see announcement.

Contact: Robert Mahon Robert.Mahon@nih.gov Objective: The scientific objectives of this new initiative are to 1) better understand the types and pathogenesis of long-term lung damage resulting from pulmonary tuberculosis (TB) and the role of the host immune response, and 2) identify ways to mitigate lung damage during TB treatment through host-directed therapy. There is no set-aside funding for this NOSI.

The Calmette & Yersin Programme internship grants aim to support Pasteur Network scientists, whether they are students, technicians, engineers or researchers to carry out an internship within the network. The purpose of the internship os to reinforce the intern's skills in his/her field of research and to reinforce the capacities of the institute of origin. Any subject covered by a Pasteur Network institute laboratory: research into infectious diseases (infectious physiopathology, immunology, microbiology, epidemiology, virology, parasitology) and public health activities (diagnosis, monitoring, resistance, etc.). It must be consistent with the candidate's research area. Calendar for 2025 Selection: 5th of March 20th of June (deadline extended) 17th of September 10th of December

Applications are now being accepted and reviewed on a rolling basis. There is no deadline to apply! The Public Health Laboratory Fellowship Program aims to strengthen laboratory systems and workforce needs by developing the next generation of public health scientists! Thus, the fellowship program will focus on training participants in alignment with established laboratory core competencies and offer experiential learning opportunities across laboratory science focus areas. Fellowship terms are one year, with a possible extension for a second year, depending on the fellowship and funding availability. ​​ APHL offers flexible start dates to meet fellow's and mentor's needs. ​ Fellows will work on projects specific to a laboratory science focus area that will support public health, One Health, and other initiatives. Below are examples of the different focus areas fellows could be matched with and placed into: Bioinformati​​​cs​ Biorisk Management Emergency Preparedness and Response Environmental Health Food Safety Infectious Disease Informatics Laboratory Operations and Support Services Quality Management Radiochemistry Ronald H. Laessig Newborn Screening​ Fellows are placed in host laboratories which include state and local public health laboratories and non-federal academic, agricultural, chemical, environmental, food safety and veterinary laboratories. Regardless of host laboratory type, the fellow will still be trained in techniques and competencies that are transferrable to a career in public health laboratory science.

Closing date: 22 September 2025 The main objectives of this funding instrument are to: Support promising clinicians who want to obtain doctoral qualifications while retaining their employment or clinical duties. Assist institutions in developing innovative and effective dual-training pathways, which provide the opportunity for PhD-level research alongside the conventional clinical training track. The award is designed to offer flexible and realistic options to clinicians who want to pursue their PhD studies. It may be used to provide protected research time from clinical training or clinical service obligations to support PhD studies undertaken in parallel with clinical activities. The use of funds is strictly for research training, i.e., obtaining a PhD. SAMRC priority research areas: Biomedical Research HIV, TB and other communicable diseases Health System Strengthening Health Promotion and Disease Prevention Maternal, child and woman health Non-communicable diseases Public Health Innovation Violence, injury and trauma

Application Deadline: 30 September 2025 The Foundation is seeking highly innovative and groundbreaking medical research proposals from top tier institutions in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health. Proposals should be distinctive and novel in their approaches, question the prevailing paradigm, and lead to advancement of knowledge in the field. All applications must be approved by the University Provost or the Vice President of Research, and should be submitted through the office of sponsored research or like office that provides institutional approval for the request. Studies selected through an internal competition are preferred. Applications submitted by an individual researcher will NOT be considered." Please refer to the link below for more specific information on this RFP.

Through the RACP Foundation, there is financial support to Fellows and trainees pursuing careers in medical research. Over 50 different fellowships, scholarships and grants are available annually, totalling over $2.5 million in funding. All applications across the different award categories will be assessed by review panels comprised of members of the Grants Advisory Committee, representatives from partner organisations, RACP Divisions, Faculties and Chapters, and other invited peer reviewers.

This Notice of Funding Opportunity (NOFO) will support students at institutions without NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD, PharmD/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a research training project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist. Please refer to the website for detail announcement and key dates.

SANTHE supports innovative research projects, trainee fellowships, collaborations, leadership development, community and public engagement, and diversity and inclusion in science.

This Notice of Funding Opportunity (NOFO) encourages R21 applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The NOFO aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. Generation of new primary data is not allowed. Please refer to the website for detail announcement and key dates.

The SAMRC’s vision is to build a healthy nation through research and innovation. For this vision to be realised, health researchers (locally and internationally) need funding to access the necessary resources and facilities. While the SAMRC funds many internal and external research projects itself, as well as in collaboration with partnering institutions, it also connects innovative researchers with like-minded organisations across the world that provide funding opportunities.

TDR supports effective and innovative global health research, through strengthening the research capacity of disease-affected countries, and promoting the translation of evidence into interventions that reduce the burden of infectious diseases and build resilience in the most vulnerable populations

The Antibacterial Resistance Leadership Group (ARLG) invites requests for industry collaboration from the ARLG in the form of advice, guidance, protocol design for drug, device, or diagnostic development. The ARLG develops, designs, implements, and manages a clinical research agenda to increase knowledge of antibacterial resistance (AR). The ARLG aims to advance research by building transformational trials that will change clinical practice and reduce the impact of antibacterial resistance and antimicrobial resistance through the following strategies: - Early clinical evaluation of new antibacterials; - Comparative effectiveness or efficacy trials; - Strategy trials to optimize currently licensed antibacterials (dose, duration, need for drug) to reduce the risk of resistance; - Clinical algorithm testing strategies; - Treatment-based prevention measures; - Diagnostics testing in the context of treatment trials, epidemiologic elements, or behavioral modification; - Effective infection control programs which include surveillance for resistant organisms, outbreak investigation, and antibiotic stewardship to prevent the development and spread of resistant organisms; - Novel facilities level activities to prevent the development of resistance.

The purpose of this program is to encourage the development of researchers in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators. The Fund will make up to 32 awards total with two funding cycles (16 awards each).

The purpose of this notice of funding opportunity (NOFO) is to support the establishment of multidisciplinary Tuberculosis (TB) Research Units (TBRUs) that will operate as a collaborative network to improve understanding of Mycobacterium tuberculosis (Mtb)-host interactions through characterizing the roles of bacterial and host heterogeneity on infection outcomes and disease progression, and defining bacterial and host determinants relevant to Mtb establishment, dissemination, and disease stage. Please refer to the website for detail announcement and key dates.

Offers funding and support across all academic disciplines and industrial areas from the medical and biological sciences to astronomy, physics, chemistry and engineering, social sciences, economics, environmental sciences, and the arts and humanities.

Unitaid supports in making new health products available and affordable for people in low- and middle-income countries. It identifies innovative treatments, tests and tools, help tackle the market barriers that are holding them back, and get them to the people who need them most – fast. It provides health partners with financial grants to accelerate innovation in global health.

The VALIDATE Network aims to accelerate vaccine research and development for three groups of complex neglected intracellular pathogens that cause significant mortality and morbidity throughout the world, particularly in low-and-middle-income countries (LMICs): Mycobacteria (causing tuberculosis, leprosy and other diseases), Leishmania (causing leishmaniasis) and Burkholderia pseudomallei (causing melioidosis). A second, important aim of the VALIDATE Network is to facilitate career progression for its members, particularly Early Career Researchers (ECRs), and (recognising career progression inequity) researchers from LMICs and researchers identifying as female and/or non-binary. CALL FOR ROUND 6 AWARDS IS EXPECTED IN DECEMBER 2025

APPLICATION DEADLINE: 19 October, 2025 The Harvard Global Health Institute is now accepting applications for our 2025-2026 cohort of Visiting Research Scholarship Program. Applications must be submitted by a Harvard faculty member, who will serve as the sponsor for an international research collaborator. This program provides funding for the Harvard sponsor to host their collaborator for a 6-week in-residence experience to complement ongoing research activities. Visiting scholars will have their in-residence time on campus financially covered through the fellowship award. Scholars will be provided with a lump sum stipend for their logistical expenses related to the visit (i.e. housing, flights to and from Cambridge, health insurance, J-1 visa fees, and daily per diem for food). The Harvard sponsor must be a Harvard faculty member at any school or affiliated hospital, and the visiting scholar should have a doctoral degree in a relevant degree. Demonstrated evidence of significant collaborative work with the sponsor, or the foundations for significant collaborative work, is required. This could be publications of peer-reviewed manuscripts, codeveloped educational curricula, partnership on policy, or service work.

Application deadline: 20 November 2025 This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding related to human life, health and wellbeing. Please refer to the website for details

Dealine for New Application: 25 November, 2025 This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing.

This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme. The applications are opened 3 times a year

Wellcome - Grants and Fundings - Searchable Database